<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03712826</url>
  </required_header>
  <id_info>
    <org_study_id>69HCL16_0811</org_study_id>
    <nct_id>NCT03712826</nct_id>
  </id_info>
  <brief_title>Identification by Cytometry by Mass of Predictive Immunological Profiles of Answer to Treatmentby Biotherapics for Patients With Crohn's Disease</brief_title>
  <acronym>PICTURE</acronym>
  <official_title>Identification by Cytometry by Mass of Predictive Immunological Profiles of Answer to Treatmentby Biotherapics for Patients With Crohn's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospices Civils de Lyon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospices Civils de Lyon</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Crohn disease is an inflammatory chronic disease of the bowel the complex physiopathology of
      which brings in immunological, genetic and environmental factors. At present, the appeal to
      biotherapics anti-TNFa (infliximab and adalimumab) or anti-IL-12/23 (ustekinumab) in MC
      represents a major therapeutic progress at the origin of a significant improvement of the
      symptoms, the healing of the intestinal hurts and the quality of life.

      Considering the new immunological targets of these biotherapics, the investigators put the
      hypothesis that an immunological profile (impulsive person and\or tissular) specific of the
      patients with one MC is associated with the answer to biotherapics. So, before beginning the
      treatment the patients expressing strongly the pro-inflammatory cytokine TNFa, would more may
      be answering machines in anti-TNFa and those with whom the immunological profile is very
      marked towards the way Th1/Th17 would more may answer favorably the ustekinumab. The
      identification of immunological profiles capable of predicting before treatment the answer
      under biotherapics could establish in MC but also in other inflammatory diseases a major step
      forward to guide the coverage.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">April 2019</start_date>
  <completion_date type="Anticipated">October 2020</completion_date>
  <primary_completion_date type="Anticipated">October 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Immunological profile</measure>
    <time_frame>Week 14</time_frame>
    <description>Identify by cytometry of mass a predictive, blood and/or mucous immunological profile, of the answer at week 14 to a biotherapics by anti-TNFa or anti IL-12 / 23 at suffering patients of Crohn disease in relapse</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mass cytometry dosage of immunological markers week 0-week 14</measure>
    <time_frame>Week 14</time_frame>
    <description>Measurements of immunological markers by mass cytometry will be performed in the blood at baseline and at week 14 and in the gastrointestinal mucosa (endoscopic biopsies) only at baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Remission at week 14</measure>
    <time_frame>Week 14</time_frame>
    <description>Clinical remission will be defined as a reduction in the CDAI score ≤ 150 at week 14.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dosage of inflammatory markers</measure>
    <time_frame>week 14</time_frame>
    <description>Assays for inflammatory blood (CRP) and fecal markers (fecal calprotectin) will be performed to predict the response to anti-TNFα or ustekinumab (anti IL-12/23) at inclusion and at week 14, with conventional methods used routinely.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Crohn Disease</condition>
  <arm_group>
    <arm_group_label>anti TNF</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Crohn patient with antiTNF treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ustekinumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Crohn disease with ustekinumab treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anti-TNF Drug</intervention_name>
    <description>Crohn patient with antiTNF treatment</description>
    <arm_group_label>anti TNF</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ustekinumab</intervention_name>
    <description>Crohn disease with ustekinumab treatment</description>
    <arm_group_label>Ustekinumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient of more than 18 years old

          -  Patient presenting a MC before diagnosed according to the usual criteria

          -  Patient in relapse (score CDAI &gt; 150) for at least 1 month

          -  requiring Patient a treatment by anti-TNF or ustekinumab according to the indications
             of the AMM

          -  Patient compatible with the realization of endoscopic digestive biopsies

          -  Patient having signed a consent of participation

        Exclusion Criteria:

        -· patient with Crohn disease with a CDAI score &lt; 150 ·

          -  contraindication to anti-TNF and\or ustekinumab ·

          -  contraindication to the realization of an iléocoloscopie

             ·- Patient taking anti-inflammatory drugs or antibiotics ·

          -  Patient presenting complications of the type intestinal sub-occlusion, fistulas or
             abdominal abscesses ·

          -  Patient having a exclusive perianal disease or having

          -  pregnant Women ·

          -  Patients having been the object of a vast intestinal resection ·

          -  Patient with an ileostomy or a colostomy ·

          -  No consent of the patient ·

          -  patient under legal protection ·

          -  Subject participating in another research which need a period of exclusion
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gilles Boschetti, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospices Civils de Lyon</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gilles Boschetti, MD</last_name>
    <phone>04.78.86.03.02</phone>
    <phone_ext>+33</phone_ext>
    <email>gilles.boschetti@chu-lyon.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Anne-Laure Charlois</last_name>
    <phone>04.78.86.37.67</phone>
    <phone_ext>+33</phone_ext>
    <email>anne-laure.charlois@chu-lyon.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Centre Hospitalier Lyon Sud</name>
      <address>
        <city>Pierre-Bénite</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gilles Boschetti, MD</last_name>
      <phone>04.78.86.03.02</phone>
      <phone_ext>+33</phone_ext>
      <email>gilles.boschetti@chu-lyon.fr</email>
    </contact>
    <contact_backup>
      <last_name>Anne-Laure Charlois</last_name>
      <phone>04.78.86.37.67</phone>
      <phone_ext>+33</phone_ext>
      <email>anne-laure.charlois@chu-lyon.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Gilles Boschetti, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Stéphane Nancey, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bernard Flourié, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>August 16, 2018</study_first_submitted>
  <study_first_submitted_qc>October 18, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 19, 2018</study_first_posted>
  <last_update_submitted>March 8, 2019</last_update_submitted>
  <last_update_submitted_qc>March 8, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 11, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Crohn</keyword>
  <keyword>immunological profile</keyword>
  <keyword>ustekinumab</keyword>
  <keyword>anti-TNF</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Crohn Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ustekinumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

